Pharmaceutical synthesis

Pharmsintez Public Joint Stock Company (MICEX: LIFE) is engaged in the research, production and distribution of active pharmaceutical substances (APIs) in Russia and other countries of the world. The company offers patented prescription drugs such as Neovir, Segidrin, Phenazide, used for the treatment of cancer, gynecological and infectious diseases.

The Company also performs API synthesis and develops custom synthesis technologies. In addition to Xemys, its pioneering products include PulmoKEN - a biological advanced version of human deoxyribonuclease-1 for cystic fibrosis, which is currently undergoing a phase II clinical trial, and Oxintolong - oxyntomodulin, designed to provide more effective delivery to the brain when administered intranasally for non-invasive treatment of obesity.

History

2023: Second highest number of clinical drug trials

At the end of 2023, 761 clinical trials of drugs were approved in Russia. Domestic pharmaceutical companies are replacing foreign drugs in terms of the number of studies carried out, and European and American organizations are replaced by manufacturers from the SCO and EAEU countries. This is stated in a study by the analytical firm Sciencefiles, the results of which were published in early February 2024.

The report says that in 2023, among domestic companies that received the most approvals in clinical drug trials, the leader changed. If in 2022 the first position was taken by Promomed with 51 projects, then in 2023 the Update company with 45 studies broke out to the top of the rating. In second place, as in 2022, was Pharmsintez - 39 projects, in third - Amedart with 34 studies. Read more here.

2022

Former Minister of Economic Development of the Irkutsk Region headed Farmsintez

On December 19, 2022, it became known about the appointment of Yevgeny Orachevsky as the new head of Farmsintez instead of Igor Moroz, who was the general director of the company from September 28, 2021. Read more here.

Pharmasintez agreed to launch production in Tajikistan

At the end of October 2022, Farmasintez agreed to launch production in Tajikistan. This became known following a meeting between the head of the Sogd region of Tajikistan Rajabb Akhmadzoda and the head of international projects of the Russian company Farmasintez Grigory Demidov.

The parties discussed issues of strengthening cooperation in the pharmaceutical sector and the implementation of a new project for the construction of a pharmaceutical production plant, the press service of the head of the Sogdi region reported.

Pharmasintez launches production in Tajikistan

Ahmadzoda informed the delegation from the Russian Federation about the state of industry and health care in the region. Demidov stressed that Farmasintez is ready to cooperate with its colleagues from the Sogdi region. The company plans to supply pharmaceutical products to Tajikistan at low prices, the press service noted.

This is not the first Pharmasintez project in the CIS countries. Earlier in 2022, the company and the Agency for the Development of the Pharmaceutical Industry under the Ministry of Health of Uzbekistan signed an agreement in the implementation of a project for the construction of a pharmaceutical enterprise for the production of antitumor drugs in the country.

The construction of the enterprise for the production of antitumor drugs "Farmasintez" plans to begin in 2023. The volume of investments is expected to be up to $30 million.

"The market of Uzbekistan, for the Pharmasintez group of companies, is one of the most important in the post-Soviet space, since this country is distinguished by a dynamically developing economy. I believe that the decision of the Government of Uzbekistan in the development of high technologies in the field of pharmaceuticals is timely and correct. After all, this is not only the development of economic and industrial potential, but also ensuring the drug safety of the country, building up technological competencies - emphasized Nikita Punia, executive director of Farmasintez Group of Companies[1]

Investing $30 million in the production of anticancer drugs in Uzbekistan

On April 25, 2022, Pharmasintez and the Agency for the Development of the Pharmaceutical Industry under the Ministry of Health of Uzbekistan signed an agreement in the implementation of the project for the construction of a pharmaceutical enterprise for the production of antitumor drugs in Uzbekistan. Up to $30 million will be invested in this project.

The construction of the Pharmasintez plant plans to begin in 2023. The company did not specify the names of the oncopreparations planned for production in Uzbekistan.

Pharmasintez invests $30 million in the production of anticancer drugs in Uzbekistan

Sardor Kariev, director of the pharmaceutical agency of Uzbekistan, said that the project will allow Pharmasintez to expand its presence not only in the market of Uzbekistan, but also in neighboring countries.

Nikita Punia, Executive Director of Farmasintez Group of Companies, called the Uzbek market one of the most important in the post-Soviet space, since this country is distinguished by a dynamically developing economy.

I believe that the decision of the Government of Uzbekistan in the development of high technologies in the field of pharmaceuticals is timely and correct. After all, this is not only the development of economic and industrial potential, but also ensuring the drug safety of the country, building up technological competencies, - he said.

According to Vikram Punia, the largest manufacturers of cancer drugs in Russia are his company, Biocad and Veropharm. He noted that Pharmasintez and Biocad produce such drugs at their own active pharmaceutical institutions. Punia estimated their consumption at 3 tons per year.

As one of the largest manufacturers of medicines in the Russian Federation, we are ready to invest in the construction of a pharmaceutical enterprise using the latest technologies, having had experience in the production of the last 25 years. We are ready to implement the project when agreeing on joint agreements, "Punia emphasized.[2]

Notes